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Association between high sensitivity C-reactive protein (hs-
CRP) levels and the risk of major adverse cardiovascular 
events (MACE) and/or microembolic signals after carotid 
angioplasty and stenting 
 
Abstract 
Background: To evaluate the association between pre/post-procedural high sensitive C-
reactive protein (hs-CRP) level and hs-CRP difference, and the risk of major adverse 
cardiovascular events (MACE) or new diffusion-weighted MRI lesions after carotid 
angioplasty and stenting (CAS). 
Methods: In this study, conducted in 2016 in Shiraz (Iran), patients who underwent 
diagnostic angiography and CAS were recruited. CAS was performed with distal embolic 
protection device on patients with both standard and high risk of endarterectomy. Pre/post-
procedural hs-CRP, and hs-CRP difference were determined by immunoenzymometric 
assay method. 
Results: A total of 50 patients with diagnostic angiography and 60 patients with CAS were 
enrolled. No death, myocardial infarction, ischemic or hemorrhagic stroke, and need to 
revascularization occurred during the 30-days of the post-procedural period. Accordingly, 
the statistical evaluation in associating MACE and hs-CRP levels was impossible. 
Angioplasty was associated with higher frequency of elevated post-procedural hs-CRP in 
comparison to angiography (P=0.003). The higher age, symptomatic lesions, negative 
history of hypertension, and hs-CRP difference had significant association with the 
presence of new DWI lesions in univariate analysis (all P<0.05). Angioplasty of left 
carotid bulb and post-procedural hs-CRP levels was very close to the level of significance 
(P=0.06). But only left sided lesions had positive association (P=0.037) and hypertension 
had negative association (P=0.037) in multivariate regression analysis. There were 
significant association between post-procedural hs-CRP level (P=0.02) and hs-CRP 
difference (P=0.003), and the number of new lesions; and the hs-CRP difference and the 
accumulated lesion surface area (P=0.009). 
Conclusion: Post-procedural hs-CRP and hs-CRP difference may predict embolic 
complications of CAS. 
Keywords: Stroke, Carotid, Angiography, Angioplasty, Inflammation, C-reactive protein, 
Complication 
Citation: 
Foroughinia F, Tabibi AA, Javanmardi H, et al. Association between high sensitivity C-reactive protein 
(hs-CRP) levels and the risk of major adverse cardiovascular events (MACE) and/or microembolic 
signals after carotid angioplasty and stenting. Caspian J Intern Med 2019; 10(4):388-395. 
 
 
Stroke is the first cause of morbidity and the third cause of mortality around the 
world (1). Large arterial stenosis is a treatable cause of ischemic stroke (2). Although 
carotid artery angiography and carotid angioplasty and stenting (CAS) are good diagnostic 
and therapeutic options in patients with severe carotid stenosis and occlusion (3, 4). 
Ischemic strokes, myocardial infarction and death are the most serious complications of 
these procedures (5). 
 Caspian J Intern Med 2019; 10(4):388-395  
hs-CRP levels and carotid angioplasty and stenting outcomes                                                    389  
CAS procedural success can be evaluated by a composite 
outcome of death, stroke, myocardial infarction (MI), or 
repeat revascularization of the target lesion similar to major 
adverse cardiovascular events (MACE) for coronary 
interventions (6). Microembolic brain infarcts represent 
emboli, which may be dislodged during a procedure (7). 
Although the rate of symptomatic presentation of these 
infarcts ranges 2%-17%, their harmful effects on cognition 
are well-established (6, 8). Hence, reducing MACE and the 
rate of microembolic signals is the most important aim in 
any CAS modification. C-reactive protein (CRP) is an 
important marker of systemic inflammation that is produced 
in the liver in response to pro-inflammatory cytokines (9). 
Serum CRP measurement, using high-sensitivity assay 
techniques (hs-CRP) enables the diagnosis of vascular 
inflammation even in the subclinical state (10). Furthermore, 
CRP also induces the release of monocyte tissue factor, 
contribute to plaque rupture and acute thrombotic events 
such as myocardial infarction and stroke (11, 12).  
Many studies have discussed the relation between hs-
CRP level and the occurrence of atherosclerotic and 
thrombotic events (MI and stroke) (13-15). Elevated baseline 
CRP is a powerful predictor for myocardial necrosis in 
patients undergoing coronary stenting (16, 17). This is a 
prospective study to evaluate whether pre-procedural hs-
CRP, post-procedural hs-CRP, and/or post-pre-procedural 
difference in hs-CRP level (hs-CRP difference) is associated 
with the risk of MACE or microembolic signals in patients 
undergoing carotid artery angioplasty and stenting. 
 
 
Methods 
Study population, demographic variables and ethics:  This 
cohort study was conducted in September to December 2016 
at Kowsar Hospital, a high-volume referral center for CAS, 
affiliated with Shiraz University of Medical Sciences, 
Shiraz, Iran. Successive patients with carotid artery stenosis 
were included in this study. Diagnostic workup such as 
Doppler sonography of intracranial and extracranial arteries, 
CT and/or MR angiography and laboratory investigations 
were performed for all patients. Those with positive history 
of active intracranial hemorrhage, cerebral infarction caused 
by cardio-aortic emboli, lacunar stroke, vasculitis, arterial 
dissection, fibromuscular dysplasia, and previous disabling 
stroke (with modified Rankin Scale score of ≥3) were 
excluded. Patients who had contraindications of angiography 
such as coagulopathy, previous allergic reactions to contrast 
media, renal failure, kidney diseases and fever with unknown 
cause were excluded from the study. Patient's demographic 
variables such as age and gender were recorded. Patients 
were also evaluated for major atherosclerotic risk factors 
such as current or previous smoking, dyslipidemia (positive 
history and/or fasting cholesterol level >200 mg/dl or fasting 
triglyceride level >180 mg/dl, or low density 
lipoprotein>130 mg/dl),  arterial hypertension (positive 
history and/or systolic blood pressure ≥140 mm Hg, diastolic 
blood pressure ≥90 mm Hg, treated or not treated), and any 
history of diabetes mellitus (positive history and/or FBS ≥ 
126 mg/dl or 2-hpp blood glucose ≥ 200 mg/dl). This study 
was approved by the local Ethics Committee of Shiraz 
University of Medical Sciences, Shiraz, Iran (No# 12616). A 
written informed consent was obtained from each patient 
before recruitment.   
Angiography and carotid stenting protocols: Cerebral 
angiography and CAS were performed according to 
standardized protocol, as previously described in detail (4). 
Patients with stenosis of more than 50% in noninvasive 
procedures underwent angiography to determine their 
treatment path. Symptomatic patients with more than 50% 
stenosis and asymptomatic patients with greater than 70% 
were recruited for stenting procedure according to NASCET 
criteria (18). Both standard and high risk patients for 
endarterectomy were included. All patients received 
antiplatelet therapy, clopidogrel (plavix) 75 mg daily with a 
loading dose of 600 mg, and aspirin 80 mg daily after a 
loading dose of 325 mg at least 48 hours (preferably four 
days) prior to the procedures. Laboratory methods to evaluate 
the resistance to anti-platelet drugs were unavailable in our 
center. Both angiography and CAS procedures were done 
under local anesthesia. Distal embolic protection device 
(EPD) was used for all patients in CAS group. Closed cell 
[Wallstent (Boston Scientific, Natick, Mass., USA)], or 
hybrid stent [Cristallo Ideale (Invatec Technology, Frauenfeld, 
Switzerland)] self-expanding stents (6-8mm diameter) was 
placed across the stenotic segment. Pre- and/or post-dilation 
was performed for those who required it. Patients were 
discharged one day after the procedure by a neurologist and 
were prescribed 75 mg of clopidogrel daily for twelve 
months and 80 mg of aspirin for the rest of their lives.  
Blood sampling procedures: CRPs were measured using 
highly-sensitive enzyme-linked immunosorbent assay 
(ELISA) kit (Monobind INC, Lake forest, CA 92630, USA) 
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with immunoenzymometric assay method. Twenty-four 
hours before and after the procedure, 5 ml fasting venous 
blood sample was collected from each patient. We calculated 
the hs-CRP level by using a standardized curve in kit 
catalogue. The cutoff value for the elevated hs-CRP was set 
at 3 mg/L.  
Post-procedural MRI technique: Post-procedural MRI was 
performed within the first 24 hours after the stenting 
procedure using Siemens MR 1.5 Tesla machine. MRI 
sequences included axial diffusion-weighted imaging (DWI), 
and apparent diffusion coefficient (ADC) (TR/ TE: 100/ 
1000, flip angle: 90, 5.5-6 mm slice thickness). Maximum 
spatial gradient magnetic field value of 3.3 Tesla/meter or 
less, and a maximum whole body averaged specific 
absorption rate (SAR wb) of 2.0W/kg for 15 minutes of MR 
scanning were considered for all procedures. To determine if 
a new ischemic lesion has occurred during the study and 
differs them from the old ones, only diffusion-restricted 
lesions (hyper-intense in DWI and hypo-intense in ADC) 
were recognized as new lesion. Presence or absence of new 
lesions, number, total accumulative surface area, and average 
surface area of the lesions (accumulated lesional surface area 
divided into number of lesions) were recorded. 
Follow-up: All patients in both groups were re-examined in 
a regular time interval (immediately after the procedure and 
on days 1 and 30) for ischemic or hemorrhagic stroke, 
myocardial infarction, need for revascularization, or any 
other post procedural complications. MACE was reported by 
a single expert neurologist who was blinded to the 
independent variables. 
Statistical analysis: Data were analyzed using SPSS Version 
16.0 (SPSS Inc., Chicago, Ill., USA).Categorical values are 
presented as counts and percentages and clinical variables 
are expressed as means ± standard deviations. In addition, t-
test and Mann Whitney test were used to compare hs-CRP 
level between groups. Chi-square test was performed to 
determine the association between qualitative variables and 
outcomes.  
The correlation between hs-CRP serum level and the 
number of new lesions was determined by Kendall's test. A P 
value (P<0.05) was considered to be statistically significant.  
Univariate logistic regression analysis was done to evaluate 
the association between the clinical and procedural variables 
and hs-CRP levels, and development of new DWI lesions. 
Due to clinical significance of some variables, multivariate 
logistic regression was performed for factors in association 
with new DWI lesions with P<0.1.  
 
 
Results 
Angiography and CAS group: A total of 50 patients who 
underwent diagnostic angiography and 60 patients who 
underwent CAS were included in this study. Thirty-three 
(66%) of patients in the angiography group and 41 (68%) in 
the CAS group were males. The mean ages were 62.7+10.71 
[95%confidence interval (CI): 59.74-65.52] in angiography 
group and 70.68+8.09 (CI: 68.61-72.61) for CAS group. 
Table-1 shows the demographic, clinical characteristics and 
percentiles of pre/post procedural hs-CRP in angiography 
and angioplasty groups.   
Table 1:  Demographic characteristics, associated diseases, and number and percentages of elevated hs-CRP 
Variable angiography group 
N=50 
CAS group 
N=60 
P value Effect size 
Mean age (years) 62.7+10.7 70.7+ 8.09 < 0.001 -1.17 
Gender , male %  33 (66%) 41 (68%) 0.795 0.025 
Weight 67.90±11.9 68.82±10.7 0.67 -0.011 
Diabetes mellitus  16 (32%) 19 (31.7%) 0.970 0.004 
Hypertension 42 (84%) 52(87%) 0.693 0.038 
Hyperlipidemia 29 (58%) 41 (68%) 0.262 0.106 
Smoking 8 (16%) 14 (23%) 0.338 0.091 
Previous TIA
1
 or stroke 27(54%) 40 (66.6%) 0.175 0.128 
Previous IHD
2
  15 (30%) 29 (48.3%) 0.051 0.183 
Elevated pre-procedural hs-CRP   14 (28%) 20 (33.3%) 0.547 0.057 
Elevated post-procedural hs-CRP  21 (42%) 39 (65%) 0.016 0.224 
                           1:TIA: transient ischemic attack    2:IHD: Ischemic heart disease 
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The angiography/plasty procedure was well endured by 
all patients. The mean stenosis of visualized carotid arteries 
in angiography group was 31.4±11.25 (CI: 27.91-34.09), and 
the mean stenosis of operated carotid arteries in CAS group 
was 81.05±13.50% (CI: 77.72-84.77). A total of 34 left 
internal carotid arteries and 26 right carotid arteries were 
stented. Embolic protection device (EPD) was used for all 
patients in the CAS group. The closed cell stent (Wallstent) 
was deployed in 41 of the participants, and the hybrid stent 
(Cristallo) was deployed in 19 patients. In the angiography 
group, mean pre-procedural hs-CRP was 4.39±9.92 mg/ml 
(CI: 1.98-7.33). In the angioplasty group, mean pre-procedural 
hs-CRP was 2.88±4.05 mg/ml (95%CI: 1.94-3.98). The post-
procedural hs-CRP in angiography and angioplasty groups 
were 9.07±24.90 mg/ml (95%CI: 2.94-16.69), and 
7.26±14.25 mg/ml (CI: 4.43-11.12), respectively. Mean hs-
CRP difference was 4.67±17.51mg/ml (95%CI: 0.46-10.38) 
in angiography group, and 4.31±13.08 mg/ml (95%CI: 2.02-
8.06) in patients underwent CAS. Hs-CRP difference in CAS 
group was significantly higher in comparison with 
angiography group (P=0.012). Table-1 showed the percentile 
of elevated post-procdural hs-CRP was significantly higher   
in angioplasty group in comparison to angiography group. 
MACE, microembolic signals and hs-CRP concentration 
in CAS group: No death, myocardial infarction, ischemic or 
hemorrhagic stroke, need of revascularization occurred 
during the 30-day post-procedural period. Table-2 shows the 
association between the demographic parameters, risk 
factors, anatomical and procedural variables, plus hs-CRP 
levels with the presence of new lesion in CAS group. The 
correlation between the hs-CRP difference and developing 
new lesions reached a statistically significant level. (P=0.01) 
Hs-CRP difference had a significant association with the 
number of new lesions (R=0.29, P=0.003) and the 
accumulated lesion surface. (R=0.38, P=0.009). There was 
also a significant association between the post-procedural hs-
CRP level and the number of ischemic lesions (R=0.22, 
P=0.02). However, the correlation between the post-
procedural hs-CRP and total lesion area did not reach a 
significant level (R=0.22, P=0.13). 
Table 2. Association of demographic variables, risk factors, anatomical/procedural variations and hs-CRP levels with 
developing new lesion in patients underwent CAS 
variables New lesion p-value Effect size 
Yes 
N=24 
No 
N=36 
Demographic variables Sex(male) 16 (66.7%) 25 (69.4%) 0.52 0.029 
Age 73.25 (70.66-75.62) 68.97 (56-69.5) 0.03 1.15 
Risk factors Diabetes Mellitus 7 )29.2%( 12 )33.3%( 0.48 0.044 
Hypertension 18 (75%) 34 (94.4%) 0.03 0.270 
Hyperlipidemia 18 (75%) 23 (63.9%) 0.26 0.116 
Smoking 5) 20.8%( 9 )25%( 0.48 0.048 
Previous IHD 9 )37.5%( 20 (55.6%( 0.134 0.174 
Symptomatic 15 )62.5%( 10 )27.8%( 0.008 0.326 
Anatomical variations Lesion Calcification 11) 45.8%( 22 )58.3%( 0.18 0.150 
Vessel side (left carotid) 17 (70.8%) 17 (47.2%) 0.06 0.227 
Contralateral stenosis (%) 
 [mean (SD) (CI)] 
20.31 (35.09) 
(6.95-33.85) 
50.0 (57.73) 
(0-100) 
0.23 -0.59 
Ipsilateral stenosis (%) 
[mean SD) ( (CI)] 
79.68 (35.09) 
(66.14-93.4) 
67.50 (47.16) 
(17.5-100) 
0.28 
0.385 
Procedural variations Intraprocedure hypotension 3 )12.5%( 5 )13.9%( 0.58 0.035 
Post-procedure hypotension 16 (66.7%) 21)58.33%( 0.34 0.032 
Pre-dilation 16 )66.7%( 24 )66.7%( 0.6 0.053 
Post-dilation 4(16.7%) 8 (22.9%) 0.4 0.085 
Duration of Procedure 
[mean (SD)] 
19.37(6.39) 17.41 (5.79) 0.22 
0.44 
Stent type (hybrid( 5 )20.8%( 14 )38.9%( 0.11 0.206 
Hs-CRP level Pre-procedural  
[mean (SD) (CI)] 
2.75 (3.06) 
(1.7-4.11) 
2.97 (4.63) 
(1.7-4.63) 
0.79 0.073- 
Post-procedural 
[mean (SD) (CI)] 
9.90 (20.79) 
(4.8-19.64) 
5.49 (7.10) 
(3.55-7.94) 
0.06 0.42 
Post-pre difference 
[mean (SD) ( CI)] 
6.98(19.95) 
(2.42-15.96) 
2.52(4.29) 
(1.42-4.08) 
0.01 0.4742 
          SD: standard deviation, CI: 95% confidence interval 
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The higher age, symptomatic lesions, negative history of 
hypertension and hs-CRP difference had significant 
association with the presence of DWI lesions in univariate 
analysis. Angioplasty of left carotid bulb and post-procedural 
hs-CRP levels was very close to the level of significance 
(P=0.06) (Table-2). Multivariate analysis for the 
abovementioned variables revealed that the risk of 
developing new ischemic lesions was significantly 
associated with left sided lesions (P=0.04), adjusted odds 
ratio (OR): (3.76, 95% CI: 1.08-13.13), and reversely 
associated with the history of hypertension) P=0.041, 
adjusted OR: 0.15, 95%CI: 0.02-0.93). The association 
between hs-CRP difference and evolution of DWI lesions 
remained in multivariate analysis model but it was not 
statistically significant (P=0.319, adjusted OR: 1.07, 95% 
CI: 0.94 -1.22). 
 
 
Discussion 
In this prospective study, the association between hs-
CRP levels and major complication of CAS was evaluated. 
Angioplasty was associated with higher frequency of 
elevated post-procedural hs-CRP in comparison to 
angiography. During the 30-day follow-up there was no 
patient with MACE. 40% of patients who underwent CAS 
had mircroembolic signals in post-procedural MRI.  Even 
though the hs-CRP difference, post-procedural hs-CRP, 
higher age, and symptomatic lesions   were associated with 
microembolic signals after CAS in univariate regression 
model, there were no significant associations in multivariate 
regression analysis. Left sided lesions were associated with 
evolution of microembolic signals and current or any 
previous history of hypertension had protective effect on the 
development of microembolic events in multivariate 
regression analysis.  
There was a significant association between post-
procedural hs-CRP level and hs-CRP difference, and the 
number of new lesions. There was a significant association 
between the hs-CRP difference and the accumulated lesion 
surface area.  
Elderly patients (19, 20), symptomatic lesions (20) and 
left sided lesions (4) were associated with more embolic 
complications in previous studies. But negative association  
of hypertension and microeicmbolic signals, seen in current 
study was contrary to previous studies (19). We cannot 
explain this negative association since chronic hypertension 
is actually associated with impaired collaterals. Hs-CRP is a 
systemic inflammatory marker that is produced in large 
amount by hepatocytes in response to interleukin-1 (IL-1), 
interleukin-6 (IL-6) and tumor necrotic factor-α (TNF-α) 
after ischemic stroke (9, 21). There are several studies that 
have shown the diagnostic and prognostic role of hs-CRP in 
ischemic stroke (13). 
In the present study, pre-procedural hs-CRP levels were 
not significantly different between patients with and without 
new lesions in CAS group.  This finding is inconsistent with 
the results of Setacci et al., and Groschel et al., studies (22, 
23). Groschel et al., showed that pre-procedural CRP is a 
predictor of stroke and death within 30 days after CAS (23). 
Also, Pini et al.’s study proved that the number of 
microembolic brain infarcts in patients with more than 5 
mg/L hs-CRP concentration is significantly higher (24).  
Meanwhile, elevated hs-CRP serum concentration after 
CAS was associated with a higher risk of microembolic 
signals in univariate analysis. Several mechanisms can 
explain the increased risk of thromboembolic events in 
patients with post-procedural elevated hs-CRP. Hs-CRP 
aggregation in human serum can trigger the complement 
pathway and induce the release of inflammatory mediators 
(25). These inflammatory processes can directly damage the 
endothelial cells and disrupt its function (26). Thus, the 
tissue factor expression and formation of procoagulant 
microparticles increase and enhance the risk of clot 
formation (27). Hs-CRP also activates macrophages and 
metalloproteinase pathway, which is an indicator for 
presence of macrophages and T lymphocytes in arterial 
plaques (28). This makes the carotid plaques unstable and 
increases the risk of plaque rupture and microembolization. 
Our results were consistent with some previous studies. In 
Jia et al.’s study, the levels of hs-CRP, TNF-α, soluble 
intercellular adhesion molecule-1(sICAM-1), interleukin-8 
(IL-8), fibrinogen and D-dimer had significantly increased in 
the CAS group, in comparison with diagnostic angiography 
group (29). The significant difference of hs-CRP level 
between CAS and diagnostic angiography in the current 
study can be explained by the inflammatory effects of stent 
implantation. Carotid angioplasty and stent deployment 
apply a transient retraction to the smooth muscle cells of the 
vessel wall that activates the inflammatory phase of vessel 
restoration and increases the concentration of inflammatory 
markers such as CRP in the serum (30, 31). While stenting, 
injury to intima and media layer and penetration of lipid core 
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may induce perivascular inflammatory responses (31, 32) 
and since stent is a foreign object, it can trigger the 
immunoinflammatory responses resulting in elevated hs-
CRP level. Furthermore, release of metal ions by stent 
material induces inflammatory reactions (33). Abe et al., 
showed that IL-6 and osteopontin were produced in the site 
of CAS (34). Moreover, CRP, IL-6 and TNF-α levels 
increased immediately after CAS in Xia et al., study (35). 
Interestingly, CRP, IL-6 and TNF-α levels were associated 
with number of stents. Employing the drug-eluting stents, 
biodegradable stents or combination of these two types (such 
as hybrid stents) can potentially decrease the inflammatory 
responses due to anti-proliferative, anti-coagulative, and 
anti-inflammatory effects (33). It is preferred to use less 
immunogenic materials and preemptive immune therapy in 
patients undergoing CAS (33).  
Relatively, low sample volume, short follow-up period, 
lack of evaluation of high density protein, and lack of 
evaluation of other “upstream/downstream” inflammatory 
biomarkers were the major shortcomings of this study. As a 
conclusion, the presence of some correlations between new 
diffusion- weighted MRI lesions and post-procedural hs-
CRP with hs-CRP difference may reveal an inflammatory 
mechanism in the embolic complications of CAS. Utilizing 
drug-eluting or biodegradable stents (33), or less 
immunogenic stent materials (34), and preemptive immune 
therapy for CAS might have had therapeutic implications in 
the current and previously-mentioned studies. Several phase 
III trials were performed with drugs that had led to marked 
reductions in IL-6 and C-reactive protein (such as 
canakinumab and methotrexate for prevention of acute 
vascular events) (35, 36). 
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